What is the significance of mesothelial cells and inflammatory cells in pleural fluid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Significance of Mesothelial Cells and Inflammatory Cells in Pleural Fluid

The presence of mesothelial cells and inflammatory cells in pleural fluid is diagnostically significant but fundamentally limited: these cells cannot reliably distinguish between benign reactive processes and malignancy, particularly mesothelioma, and tissue biopsy is required for definitive diagnosis in most cases.

Diagnostic Limitations of Mesothelial Cells

The Core Problem: Distinguishing Benign from Malignant

The critical challenge with mesothelial cells in pleural fluid is that cytological features alone cannot differentiate between reactive mesothelial proliferation and malignant pleural mesothelioma (MPM) 1, 2. Many mesotheliomas lack significant cytological atypia, making this distinction impossible on morphology alone 1.

Cytology sensitivity for mesothelioma is only 26.9-58% 3, 4, which is unacceptably low for definitive diagnosis. When "atypical" and "suspicious" categories are included, sensitivity increases only to 46.2% 4. This poor performance stems from:

  • Difficulty differentiating malignant from reactive mesothelial cells
  • Sample preparation issues
  • Extent of disease (only 30% of cytology-negative cases had visceral pleural involvement versus 82% of cytology-positive cases) 2

When Mesothelial Cells Suggest Specific Diagnoses

The term "atypical mesothelial proliferation" should be used when mesothelial cells show variable atypia but malignancy cannot be confirmed 1. This diagnosis:

  • Does not confirm MPM but leaves the possibility open
  • Mandates tissue biopsy for definitive diagnosis
  • May warrant ancillary testing (FISH for p16 deletion, BAP1 immunohistochemistry) 1, 2, 5

Inflammatory Cells: What They Tell You

Cell Type Distribution and Diagnostic Clues

Pleural fluid eosinophilia (>25% lymphocytes is unusual) does not exclude malignant effusion 3. The inflammatory cell profile provides limited diagnostic specificity but can suggest certain conditions:

  • Lymphocyte-predominant effusions: Consider tuberculosis (though ADA levels are more useful) 6
  • Mixed inflammatory cells: Most commonly seen in reactive processes but also present in malignancy 4
  • Macrophages: Non-specific finding in various benign and malignant conditions 4

Inflammatory Cells in Mesothelioma Pathophysiology

Recent evidence demonstrates that inflammatory cells actively participate in mesothelioma progression and treatment resistance 7. Specifically:

  • Chemotherapy alters the lipid mediator composition by reducing specialized pro-resolving mediators (SPMs)
  • This creates a pro-tumorigenic, pro-inflammatory microenvironment
  • Impaired resolution of inflammation contributes to chemoresistance 7

Mesothelial cells themselves mediate inflammatory responses through production of IL-6, IL-8, IL-1β, TNF-α, VEGF, and TGF-β1 8, 9, 10. The NF-κB/IL-6/STAT3 pathway plays a central role in malignant transformation 10.

Clinical Algorithm for Interpretation

Step 1: Initial Cytology Assessment

  • If malignant cells definitively identified: Proceed with immunohistochemistry on cell block to distinguish mesothelioma from adenocarcinoma
    • Use CEA, Leu-1, mucin (positive in 50-90% of adenocarcinomas, 0-10% in mesothelioma) 3
    • Claudin-4 shows 99% sensitivity for adenocarcinoma versus mesothelioma 2

Step 2: If Cytology Shows Only Mesothelial Cells

Do not rely on cytology alone—proceed directly to tissue biopsy 2:

  • Thoracoscopy with multiple biopsies (>95% diagnostic yield) 2
  • CT-guided core biopsy if nodular pleural thickening present
  • Blind pleural biopsies are NOT recommended due to low yield (40-75%) and complications 1, 3

Step 3: Ancillary Testing on Tissue

When tissue obtained, supplement with:

  • Positive mesothelioma markers: Calretinin, cytokeratin 5/6, WT1, podoplanin 2
  • Negative mesothelioma markers: CEA, EPCAM, Claudin 4, TTF-1 2
  • Molecular testing: FISH for p16/CDKN2A deletion (100% specificity, 14-85% sensitivity); BAP1 loss by IHC; MTAP loss (96% specificity, 86% sensitivity) 5

Critical Pitfalls to Avoid

  1. Never diagnose mesothelioma on cytology alone—immunohistochemical studies have limited value for distinguishing mesothelioma from benign mesothelial cells 2

  2. Do not assume negative cytology excludes malignancy—53.8% of proven mesothelioma cases had negative pleural fluid cytology initially interpreted as "reactive mesothelial cells" 4

  3. Recognize that "nonspecific pleuritis" on biopsy may represent false-negative mesothelioma—8% (range 3-38%) eventually prove malignant, most commonly MPM 5. Risk factors for false-negative include:

    • Recurrent pleural effusion
    • Ipsilateral chest pain
    • Asbestos exposure history
    • CT findings: parietal pleural thickening >1 cm, nodular thickening, circumferential involvement 5
  4. Understand that mesothelioma in situ can take 1-15 years to progress to invasive disease 5—a single negative biopsy does not provide permanent reassurance

Prognostic Significance

Beyond diagnosis, inflammatory markers in pleural fluid have prognostic implications:

  • Low pH (≤7.28) and low glucose (<60 mg/dL) indicate higher tumor burden, worse survival, and potentially worse pleurodesis response 3
  • However, pH has insufficient predictive accuracy to guide treatment decisions alone and must be combined with performance status, tumor type, and clinical response 3

The bottom line: Mesothelial and inflammatory cells in pleural fluid serve primarily as screening tools that prompt further investigation rather than providing definitive diagnostic information. Tissue biopsy with immunohistochemistry and molecular testing remains the gold standard for diagnosis 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.